ENSC - Ensysce Biosciences, Inc. Stock Price, Fair Value and News

0.61USD+0.02 (+3.39%)Market Closed

Market Summary

USD0.61+0.02

Market Closed

3.39%

ENSC Stock Price

View Fullscreen

ENSC RSI Chart

ENSC Valuation

Market Cap

4.5M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

EV/EBITDA

2.72

Price/Free Cashflow

-0.41

ENSC Price/Sales (Trailing)

ENSC Profitability

EBT Margin

89.05%

Return on Equity

1.6K%

Return on Assets

-392.39%

Free Cashflow Yield

-241.12%

ENSC Fundamentals

ENSC Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-64.07%

Rev. Growth (Qtr)

18.29%

ENSC Earnings

Earnings (TTM)

-10.6M

Earnings Growth (Yr)

36.03%

Earnings Growth (Qtr)

-30.23%

Breaking Down ENSC Revenue

Last 7 days

5.4%

Last 30 days

-25.3%

Last 90 days

-63.6%

Trailing 12 Months

-84.0%

How does ENSC drawdown profile look like?

ENSC Financial Health

Current Ratio

0.69

Debt/Equity

-7.68

Debt/Cashflow

-2.16

ENSC Investor Care

Shares Dilution (1Y)

488.61%

Diluted EPS (TTM)

-1.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.7M	3.0M	3.1M	2.2M
2022	3.9M	3.6M	2.7M	2.5M
2021	3.8M	3.7M	3.6M	3.5M
2020	0	0	0	3.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ensysce Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 02, 2023	gower bob g	bought	44,087	0.4883	90,287	-
Mar 01, 2023	gower bob g	bought	128,979	0.4777	270,000	-
Feb 28, 2023	gower bob g	bought	53,371	0.4883	109,300	-
Dec 09, 2022	gower bob g	bought	500,000	1.4	357,143	-
May 26, 2022	kirkpatrick lynn	bought	14,215	0.5265	27,000	chief executive officer
May 25, 2022	kirkpatrick lynn	bought	34,083	0.4869	70,000	chief executive officer
Jun 30, 2021	gower bob g	acquired	-	-	7,919,030	-
Jun 30, 2021	kirkpatrick lynn	acquired	-	-	284,851	chief executive officer
Jun 30, 2021	chang william h	acquired	-	-	2,242,190	-
Jun 30, 2021	chang william h	acquired	-	-	353,451	-

Which funds bought or sold ENSC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	17.87	-2,012	19,266	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-81.00	-	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-133,823,000	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-20,170	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-26,185	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	60.65	1,267	6,685	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-312	1,034	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	reduced	-0.91	-5,496	17,013	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	12,000	12,000	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	added	14.29	-4.00	25.00	-%

Are Funds Buying or Selling ENSC?

Are funds buying ENSC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENSC

No. of Funds

Unveiling Ensysce Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lincoln park capital fund, llc	792%	124,008	SC 13G/A
Jul 18, 2023	gower bob g	5.7%	161,586	SC 13D/A
Feb 14, 2023	hg vora capital management, llc	2.1%	237,750	SC 13G/A
Feb 14, 2023	cvi investments, inc.	4.9%	336,872	SC 13G/A
Feb 07, 2023	lincoln park capital fund, llc	9.99%	1,501,055	SC 13G
Dec 16, 2022	cvi investments, inc.	7.8%	5e+05	SC 13G
Feb 14, 2022	hg vora capital management, llc	24.6%	7,130,000	SC 13G/A
Feb 14, 2022	glazer capital, llc	0.0%	0	SC 13G/A

Recent SEC filings of Ensysce Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	POS AM	POS AM
Apr 05, 2024	EFFECT	EFFECT
Mar 29, 2024	8-K	Current Report
Mar 26, 2024	S-1/A	Initial Public Offering
Mar 15, 2024	8-K	Current Report
Mar 15, 2024	10-K	Annual Report
Feb 21, 2024	D	D
Feb 15, 2024	424B3	Prospectus Filed
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	8-K	Current Report

Peers (Alternatives to Ensysce Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	3.52%	-17.31%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-3.68%	-28.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-7.53%	-16.73%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-8.64%	-30.91%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-24.84%	-46.72%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-17.14%	78.66%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-20.91%	-36.67%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	-9.41%	-43.91%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-5.61%	336.79%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-17.51%	25.55%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-57.88%	56.88%	-0.24	2.14	-13.45%	66.37%

Ensysce Biosciences, Inc. News

Latest updates

Ensysce Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	18.3%	515	435	490	790	1,433	279	207	603	1,635	1,201	445	251	539	828	1,825
Operating Expenses	16.8%	3,671	3,143	2,784	3,351	7,634	6,443	7,263	5,406	3,662	18,088	857	775	1,611	1,232	1,686
S&GA Expenses	17.1%	1,438	1,228	1,141	1,555	1,099	1,687	1,951	2,266	1,454	16,373	394	490	256	339	281
R&D Expenses	16.6%	2,233	1,915	1,644	1,796	6,535	4,756	5,311	3,140	2,208	1,715	463	284	1,253	893	1,404
EBITDA Margin	61.4%	1.05*	0.65*	0.68*	0.77*	0.83*	0.75*	0.57*	0.76*	0.93*	1.01*	1.03*	0.82*	1.65*	-	-
Interest Expenses	4407.8%	345	8.00	-	1.00	52.00	5.00	38.00	15.00	12.00	25.00	910	348	397	216	202
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	2.00	-131	-504	694
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-1,772	741	-285	3,304
EBT Margin	41.2%	0.89*	0.63*	0.66*	0.73*	0.79*	0.73*	0.54*	0.51*	0.56*	0.55*	0.53*	0.52*	1.43*	-	-
Net Income	-30.2%	-3,504	-2,690	-2,239	-2,191	-5,478	-9,855	-7,923	-950	-10,057	-17,199	-957	-911	-2,207	1,571	887
Net Income Margin	-19.1%	-4.76*	-4.00*	-6.60*	-9.39*	-9.59*	-10.56*	-9.91*	-7.51*	-8.25*	-5.86*	-0.67*	-0.17*	0.52*	-	-
Free Cashflow	20.4%	-1,801	-2,262	-3,108	-3,606	-3,295	-6,714	-4,440	-3,437	-3,767	-3,824	-132	-517	-533	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-15.9%	2,708	3,219	6,358	3,915	5,885	8,290	7,949	12,371	16,417	9,718	9,196	12,980	13,135	13,289	13,412	61,602	196,512	207,211	206,357	205,555	204,832
Current Assets	-17.0%	2,289	2,758	5,855	3,371	5,299	7,662	7,195	11,658	15,663	8,921	8,358	228	348	102	186	274	1,200	1,378	1,469	1,611	1,916
Cash Equivalents	-23.3%	1,124	1,464	3,829	1,416	3,148	4,503	3,735	8,441	12,265	6,846	8,012	18.00	194	53.00	124	168	1,061	1,274	1,402	1,507	1,658
Net PPE	-	-	-	-	-	-	-	-	-	-	-	50*	100*	151*	-	-	-	351*	-	-	-	-
Liabilities	63.0%	3,359	2,061	2,565	4,067	9,915	14,712	8,747	11,260	24,575	10,103	4,029	11,087	7,010	11,774	16,107	57,084	17,504	13,662	13,162	12,779	13,173
Current Liabilities	64.1%	3,333	2,031	2,517	3,976	9,464	11,910	8,248	8,802	16,482	7,031	4,029	319	7,010	452	794	3,494	2,771	1,125	327	387	438
Long Term Debt	-	-	-	-	-	-	5,000	5,000	-	593	5,000	-	-	670	-	-	-	-	-	-	-	-
Shareholder's Equity	-143.9%	-651	1,485	3,793	167	-4,029	-	-	1,111	-8,158	-	5,167	1,894	5,000	1,515	5,000	4,518	49,512	5,000	5,000	5,000	5,000
Retained Earnings	-3.0%	-121,557	-118,052	-115,400	-113,100	-110,931	-105,409	-95,511	-87,500	-85,845	-75,005	-57,841	-2,919	-55,958	1,514	-2,695	1,656	-136	2,820	2,467	2,048	931
Additional Paid-In Capital	1.4%	121,234	119,538	119,482	113,294	107,217	99,314	95,016	88,900	77,967	74,897	63,251	4,813	49,518	63.00	-	2,861	5,136	2,179	2,533	2,952	4,069
Shares Outstanding	9.8%	3,146	2,864	2,670	1,285	534	139	128	114	103	101	26.00	66.00	66.00	-	-	-	-	-	-	-	-
Minority Interest	-0.3%	-328	-327	-326	-319	-315	-327	-305	-279	-279	-279	-243	-221	-217	-	-	-	-	-	-	-	-
Float	-	-	-	4,600	-	-	-	18,800	-	-	-	-	-	-	-	3,700	-	-	-	193,800	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	20.4%	-1,801	-2,262	-3,108	-3,606	-3,295	-6,714	-4,440	-3,437	-3,767	-3,824	-132	-517	-533	-152	-326	-234	-425	-272	-432	-294	-458
Share Based Compensation	1029.7%	629	56.00	77.00	117	217	157	296	402	17.00	25.00	36.00	44.00	59.00	52.00	36.00	32.00	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	5.00	-	-	-	-62.50	183,407	-182,807	48,179	134,625	11,230	144	328	151	363
Cashflow From Financing	1526.1%	1,461	-102	5,522	1,875	1,940	7,483	-265	-391	9,187	2,659	7,854	613	-	300	136,084	-135,283	-11,017	-	-	-8.64	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136,283	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENSC Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Federal grants	$ 2,230,520	$ 2,523,383
Operating expenses:
Research and development	7,587,473	19,835,875
General and administrative	5,361,234	6,909,603
Total operating expenses	12,948,707	26,745,478
Loss from operations	(10,718,187)	(24,222,095)
Other income (expense):
Loss on issuance of convertible notes		(3,609,944)
Issuance costs for convertible notes		(1,137,740)
Loss on conversions and change in fair value of convertible notes	146,479	1,792,154
Issuance of liability classified warrants		(3,737,371)
Change in fair value of liability classified warrants	283,958	6,730,613
Interest expense, net	(353,945)	(109,525)
Other income and expense, net	15,420	86,223
Total other income (expense), net	91,912	14,410
Net loss	(10,626,275)	(24,207,685)
Net loss attributable to noncontrolling interests	(13,201)	(35,393)
Deemed dividend related to warrants down round provision	12,937	913,204
Net loss attributable to common stockholders	$ (10,626,011)	$ (25,085,496)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic	$ (4.69)	$ (139.42)
Net loss per share attributable to common stockholders, diluted	$ (4.69)	$ (139.42)
Weighted average common shares outstanding, basic	2,264,060	179,925
Weighted average common shares outstanding, diluted	2,264,060	179,925

ENSC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,123,604	$ 3,147,702
Unbilled receivable	97,561	276,821
Right-of-use asset		27,165
Prepaid expenses and other current assets	1,067,703	1,847,481
Total current assets	2,288,868	5,299,169
Property and equipment, net
Other assets	419,217	585,883
Total assets	2,708,085	5,885,052
Current liabilities:
Accounts payable	1,936,007	2,943,791
Accrued expenses and other liabilities	542,260	2,226,494
Lease liability		27,315
Notes payable and accrued interest	854,697	4,266,610
Total current liabilities	3,332,964	9,464,210
Long-term liabilities:
Notes payable, net of current portion (at fair value)		140,148
Other long-term liabilities	26,388	310,346
Total long-term liabilities	26,388	450,494
Total liabilities	3,359,352	9,914,704
Commitments and contingencies (Note 6)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2023 and December 31, 2022; 3,146,157 and 534,571 shares issued at December 31, 2023 and December 31, 2022, respectively; 3,146,076 and 534,490 shares outstanding at December 31, 2023 and December 31, 2022, respectively	315	53
Additional paid-in capital	121,233,901	107,216,566
Accumulated deficit	(121,557,074)	(110,931,063)
Total Ensysce Biosciences, Inc. stockholders’ deficit	(322,858)	(3,714,444)
Noncontrolling interests in stockholders’ deficit	(328,409)	(315,208)
Total stockholders’ deficit	(651,267)	(4,029,652)
Total liabilities and stockholders’ deficit	$ 2,708,085	$ 5,885,052

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

CEO	Dr. D. Lynn Kirkpatrick Ph.D.
WEBSITE	ensysce.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Ensysce Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Ensysce Biosciences, Inc.? What does ENSC stand for in stocks?

ENSC is the stock ticker symbol of Ensysce Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ensysce Biosciences, Inc. (ENSC)?

As of Tue Apr 30 2024, market cap of Ensysce Biosciences, Inc. is 4.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENSC stock?

You can check ENSC's fair value in chart for subscribers.

What is the fair value of ENSC stock?

You can check ENSC's fair value in chart for subscribers. The fair value of Ensysce Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ensysce Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENSC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ensysce Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENSC is over valued or under valued. Whether Ensysce Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ensysce Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENSC.

What is Ensysce Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ENSC's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 1.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENSC PE ratio will change depending on the future growth rate expectations of investors.